Let CRISPR/Cas9 battle commence

The US Patent and Trademark Office (USPTO) has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

Europe

Are the Broad Institute’s CRISPR patents too broad?

29 October 2015 Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.

Americas

Regeneron agrees CRISPR/Cas licensing deal

14 April 2016 Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.